welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Guides & Guidelines
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene
source: National Institute for Health and Care Excellence
year: 2016
summary/abstract:This guidance is not intended to affect the position of patients whose treatment with ataluren was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.
read morerareRelated
-
Ataluren: An Overview of Clinical Trial Results in Nonsense Mutation Duchenne Muscular DystrophyObjective: Provide an overview of atalu...
-
The PTC124 (Ataluren) Clinical Trial for Duchenne Muscular Dystrophy: Exploration of the Experiences of Parents, Cli...The purpose of this study is to describe...
-
Boy with muscular dystrophy writes heartfelt note to Scottish leaderMichael Young, 9, wrote a letter to Scot...
-
Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation DystrophinopathyThe main goal of this Phase 3 extension ...
-
Ataluren treatment of patients with nonsense mutation dystrophinopathyIntroduction: Dystrophinopathy is a ra...
-
PTC Therapeutics Announces Initial Data from Patient Registry Demonstrating Translarna™ (ataluren) Slows Disease P...PTC Therapeutics, Inc. today announced p...
-
PTC Therapeutics Announces Positive Data from its Translarna™ Phase II Clinical Trial in Children as Young as Two ...PTC Therapeutics, Inc. today announced t...